Physician profile
Donald Benefield
NPI 1386636694
$6,266.10
in general payments reported to CMS, 2019-2025
31 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $502 · 2021: $836 · 2022: $1,079 · 2023: $626 · 2024: $1,242 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.20 |
| Education | $213.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,225.53 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Allergan, INC. | $796.51 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $726.71 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $658.22 | 2019-2025 | Clareon Panoptix Pro, Argos, Clareon |
| Mallinckrodt Hospital Products INC. | $549.82 | 2021-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $277.11 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $249.72 | 2024-2025 | Xdemvy |
| Amgen INC. | $239.90 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $165.00 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $149.05 | 2022-2024 | Miebo, Vyzulta, Biotrue One Day |
| Biotissue Holdings INC. | $142.39 | 2019-2025 | |
| Alimera Sciences, INC. | $132.98 | 2019-2024 | Yutiq, Iluvien |
| Ani Pharmaceuticals, INC. | $107.00 | 2025 | Iluvien, Yutiq |
| Glaukos Corporation | $99.13 | 2019-2023 | |
| Dompe US, INC. | $89.97 | 2024-2025 | Oxervate |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $83.63 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $69.19 | 2019-2021 | |
| Horizon Therapeutics Plc | $62.23 | 2021-2023 | Tepezza |
| Ocular Therapeutix, INC. | $51.81 | 2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $49.76 | 2019-2021 | |
| Iridex Corporation | $45.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.07 | 2020 | |
| Shire North American Group INC | $35.43 | 2019 | |
| Beaver-Visitec International, INC. | $35.14 | 2019 | |
| Rayner Intraocular Lenses Limited | $34.70 | 2025 | Omidria |
| Apellis Pharmaceuticals, INC. | $31.35 | 2024 | Syfovre |
| Harrow Eye, LLC | $30.98 | 2024 | Vevye |
| Johnson & Johnson Vision Care, INC. | $27.11 | 2021-2022 | |
| Sight Sciences, INC. | $25.92 | 2021-2025 | Sion Surgical Instrument, Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $21.57 | 2024 | Eylea Hd |
| Eyevance Pharmaceuticals LLC | $16.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Benefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.